Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 19/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 9/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.67 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sc-41390 SCHEMBL29369604 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| Sc-41390 SCHEMBL29403478 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| Sc-41390 SCHEMBL6372085 | 0.99 | LTB4R (0.98) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL5694768 | 0.97 | LTB4R (0.95) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL5694802 | 0.95 | LTB4R (0.90) | LTB4RLTB4R2 | |
| SCHEMBL9821725 | 0.93 | LTB4R (0.87) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL9821676 | 0.93 | LTB4R (0.86) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL7744035 | 0.92 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL8877600 | 0.92 | LTB4R (0.85) | LTB4RLTB4R2 | |
| Sc-41390 SCHEMBL6372088 | 0.91 | LTB4R (0.84) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| WO-2018071687-A1 | METHODS OF TREATING PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-19 | — | — | WO | claimed |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2017-11-23 | — | — | US | claimed |
| US-20110105959-A1 | Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. (US) | 2011-05-05 | — | — | US | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| EP-1628630-A4 | METHOD OF MITIGATING THE ADVERSE EFFECTS OF IL-2 | INTARCIA THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1628630-A2 | METHOD OF MITIGATING THE ADVERSE EFFECTS OF IL-2 | Intarcia Therapeutics, Inc. (US) | 2006-03-01 | — | — | EP | claimed |
| US-6933272-B1 | Use of non-peptidyl compounds for the treatment of insulin related ailments | HELMERHORST ERIK (AU) | 2005-08-23 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| WO-2004108077-A2 | METHOD OF MITIGATING THE ADVERSE EFFECTS OF IL-2 | BIOMEDICINES, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| EP-1129707-A2 | Methods for identifying and treating resistant tumors | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-09-05 | — | — | EP | claimed |
| EP-1115422-A1 | USE OF NON-PEPTIDYL COMPOUNDS FOR THE TREATMENT OF INSULIN RELATED AILMENTS | CURTIN UNIVERSITY OF TECHNOLOGY (AU) | 2001-07-18 | — | — | EP | claimed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2000016798-A1 | USE OF NON-PEPTIDYL COMPOUNDS FOR THE TREATMENT OF INSULIN RELATED AILMENTS | CURTIN UNIVERSITY OF TECHNOLOGY (AU) | 2000-03-30 | — | — | WO | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0777472-A2 | METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1997-06-11 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| US-5543428-A | ADMINISTERING SUBSTITUTED PHENOXYALKYL COMPOUNDS TO REVERSE DRUG RESISTANCE | ELI LILLY AND COMPANY (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996006604-A2 | METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-03-07 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | LTB4R 60/4885LTB4R2 45/4885CYSLTR2 48/4885 |
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | LTB4R 8/4885LTB4R2 4/4885CYSLTR2 2/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | LTB4R 61/4885LTB4R2 56/4885CYSLTR2 71/4885 |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | LTB4R, LTA4H, LTB4R2 | LTB4R 1/4885LTB4R2 3/4885CYSLTR2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.